Off-site supervision of the pharmaceutical industry: Hebei can manufacture "Beijing medicine"

  • time:
  • Views: 133
  • Source: Dongyang Information Network

    Original title: Hebei made a remote supervision of "Beijing Medicine"

    Recently, Cangzhou Branch of Beijing Langyi Pharmaceutical Co., Ltd. started trial production. 300 kilograms of pidotimod APIs came out in Beijing · Cangzhou Bohai New Area Biopharmaceutical Industrial Park, and then were shipped to Beijing Head Office. This is the first batch of pharmaceuticals produced by Beijing pharmaceutical companies to migrate abroad to Hebei.

    "The company was the first to obtain a trial production license issued by the Beijing Food and Drug Administration through remote supervision." Ji Weiwei, manager of the Beijing Langyi Cangzhou Branch, said with excitement that the company still retains "Beijing status", and the Beijing Food and Drug Administration The bureau has implemented licensing, certification, and supervision, which is the first of its kind in the country.

    Restricted by environmental and land factors, Beijing's pharmaceutical industry is in urgent need of dissolution, and chemical raw material drug manufacturing will all be withdrawn from Beijing by the end of 2017. After various inspections, Beijing finally chose to build the Beijing · Cangzhou Bohai New Area Biomedical Industrial Park in Cangzhou Lingang Economic and Technological Development Zone. This is the first specialized industrial park under Beijing-Tianjin-Hebei cooperation.

    After that, the two places in Beijing and Hebei explored the implementation of a remote supervision of the pharmaceutical industry, that is, the Beijing-based pharmaceutical companies that concentratedly transferred to the Biopharmaceutical Industrial Park in Bohai New District, Cangzhou, Beijing. The production situation will be extended and supervised. The existing tracking inspection and flight inspection will cover the park simultaneously. The registered Beijing pharmaceutical companies still retain the “Beijing identity”, the name and registered address remain unchanged, and the corresponding product approval document number will not be transferred, and will be handled in accordance with the change of production address. On April 11, 2015, the first batch of 10 Beijing pharmaceutical companies started construction in Beijing · Cangzhou Bohai New Area Biopharmaceutical Industrial Park. (Reporter Guo Tao)

    (Responsible editor: Li Xingxing (Intern), Xiao Ling)